Detalhe da pesquisa
1.
Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia.
Br J Haematol
; 198(2): 338-348, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35468223
2.
The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey.
Ann Hematol
; 98(3): 713-722, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30680505
3.
Mutations in the plasma cell clone identify mechanism of polyneuropathy in a case of POEMS syndrome associated with Castleman disease and multiple myeloma.
Ann Hematol
; 102(1): 239-242, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36401620
4.
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.
Blood
; 125(5): 831-40, 2015 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-25428216
5.
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome.
Blood
; 123(22): 3414-9, 2014 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-24733348
6.
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.
Blood
; 122(2): 219-26, 2013 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-23699600
7.
The impact of response on bone-directed therapy in patients with multiple myeloma.
Blood
; 122(17): 2974-7, 2013 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-23974194
8.
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
Am J Hematol
; 90(7): 647-52, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25858483
9.
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.
Exp Cell Res
; 328(2): 444-55, 2014 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25257607
10.
The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
Br J Haematol
; 165(4): 441-54, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24580032
11.
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Blood
; 120(1): 9-19, 2012 Jul 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-22498745
12.
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
Ann Hematol
; 93(1): 123-8, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23864035
13.
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
Leukemia
; 38(5): 1072-1080, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38548962
14.
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.
Blood
; 118(23): 5989-95, 2011 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21900189
15.
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.
Ann Hematol
; 92(9): 1271-80, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23660628
16.
[Differences due to socio-economic status, genetic background and sex in cancer and precision medicine - An intersectional approach to close the care gap for marginalized groups]. / Unterschiede durch sozioökomische Benachteiligung, genetischen Hintergrund und Geschlecht bei Tumorerkrankungen.
Dtsch Med Wochenschr
; 148(9): 528-538, 2023 04.
Artigo
em Alemão
| MEDLINE | ID: mdl-37094588
17.
Immunogenic cell death triggered by impaired deubiquitination in multiple myeloma relies on dysregulated type I interferon signaling.
Front Immunol
; 14: 982720, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36936919
18.
Pomalidomide combinations are a safe and effective option after daratumumab failure.
J Cancer Res Clin Oncol
; 149(9): 6569-6574, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36781500
19.
A digital twin model for evidence-based clinical decision support in multiple myeloma treatment.
Front Digit Health
; 5: 1324453, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38173909
20.
Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial.
EClinicalMedicine
; 62: 102099, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37554123